DEERE & CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DEERE & CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $45.68B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $51.72B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $61.25B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $52.58B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $44.02B | Dec 15, 2023 |
| FY2020 | Nov 1, 2020 | $9.73B | Dec 17, 2020 |
| FY2020 | Aug 2, 2020 | $8.93B | Dec 17, 2020 |
| FY2020 | May 3, 2020 | $9.25B | Dec 17, 2020 |
| FY2020 | Feb 2, 2020 | $7.63B | Dec 17, 2020 |
| FY2020 | Nov 3, 2019 | $9.90B | Dec 17, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2009 | Oct 31, 2009 | $20.76B | Dec 17, 2009 |
| FY2009 | Oct 31, 2008 | $25.80B | Dec 17, 2009 |
| FY2009 | Oct 31, 2007 | $21.49B | Dec 17, 2009 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Nov 1, 2020 | $2.19B | Dec 17, 2020 |
| FY2020 | Aug 2, 2020 | $2.02B | Dec 17, 2020 |
| FY2020 | May 3, 2020 | $1.93B | Dec 17, 2020 |
| FY2020 | Feb 2, 2020 | $1.45B | Dec 17, 2020 |
| FY2020 | Nov 3, 2019 | $1.97B | Dec 17, 2020 |
| FY2020 | Jul 28, 2019 | $2.10B | Dec 17, 2020 |
| FY2020 | Apr 28, 2019 | $2.52B | Dec 17, 2020 |
| FY2020 | Jan 27, 2019 | $1.51B | Dec 17, 2020 |
| FY2019 | Oct 28, 2018 | $1.96B | Dec 19, 2019 |
| FY2019 | Jul 29, 2018 | $2.13B | Dec 19, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $5.03B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $7.10B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $10.17B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $7.13B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $5.96B | Dec 15, 2023 |
| FY2020 | Nov 1, 2020 | $757.00M | Dec 17, 2020 |
| FY2020 | Aug 2, 2020 | $811.00M | Dec 17, 2020 |
| FY2020 | May 3, 2020 | $666.00M | Dec 17, 2020 |
| FY2020 | Feb 2, 2020 | $517.00M | Dec 17, 2020 |
| FY2020 | Nov 3, 2019 | $721.00M | Dec 17, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 27, 2024 | $9.04B | Dec 12, 2024 |
| FY2024 | Oct 29, 2023 | $12.96B | Dec 12, 2024 |
| FY2024 | Oct 30, 2022 | $9.51B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $8.01B | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $4.31B | Dec 15, 2022 |
| FY2021 | Nov 3, 2019 | $4.42B | Dec 16, 2021 |
| FY2020 | Oct 28, 2018 | $4.48B | Dec 17, 2020 |
| FY2019 | Oct 29, 2017 | $3.57B | Dec 19, 2019 |
| FY2016 | Oct 31, 2016 | $2.59B | Dec 19, 2016 |
| FY2018 | Oct 30, 2016 | $2.61B | Dec 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $2.31B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $2.29B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $2.18B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $1.91B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $1.59B | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $1.64B | Dec 15, 2022 |
| FY2021 | Nov 3, 2019 | $1.78B | Dec 16, 2021 |
| FY2020 | Oct 28, 2018 | $1.66B | Dec 17, 2020 |
| FY2019 | Oct 29, 2017 | $1.37B | Dec 19, 2019 |
| FY2016 | Oct 31, 2016 | $1.39B | Dec 19, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $4.66B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $4.84B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $4.60B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $3.86B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $3.38B | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $3.48B | Dec 15, 2022 |
| FY2021 | Nov 3, 2019 | $3.55B | Dec 16, 2021 |
| FY2020 | Oct 28, 2018 | $3.46B | Dec 17, 2020 |
| FY2019 | Oct 29, 2017 | $3.10B | Dec 19, 2019 |
| FY2016 | Oct 31, 2016 | $2.76B | Dec 19, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $7.46B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $9.23B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $8.59B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $4.70B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $7.73B | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $7.48B | Dec 15, 2022 |
| FY2021 | Nov 3, 2019 | $3.41B | Dec 16, 2021 |
| FY2020 | Oct 28, 2018 | $1.82B | Dec 17, 2020 |
| FY2019 | Oct 29, 2017 | $2.20B | Dec 19, 2019 |
| FY2018 | Oct 30, 2016 | $3.77B | Dec 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $1.36B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $1.64B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $1.50B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $1.13B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $848.00M | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $820.00M | Dec 15, 2022 |
| FY2021 | Nov 3, 2019 | $1.12B | Dec 16, 2021 |
| FY2020 | Oct 28, 2018 | $896.00M | Dec 17, 2020 |
| FY2019 | Oct 29, 2017 | $595.00M | Dec 19, 2019 |
| FY2016 | Oct 31, 2016 | $644.40M | Dec 19, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $106.00B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $107.32B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $104.09B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $90.03B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $84.11B | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $75.09B | Dec 15, 2022 |
| FY2021 | Nov 3, 2019 | $73.01B | Dec 16, 2021 |
| FY2020 | Oct 28, 2018 | $70.11B | Dec 17, 2020 |
| FY2019 | Oct 29, 2017 | $65.79B | Dec 19, 2019 |
| FY2016 | Oct 31, 2016 | $57.98B | Dec 19, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $79.99B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $84.40B | Dec 18, 2025 |
| FY2024 | Oct 29, 2023 | $82.20B | Dec 12, 2024 |
| FY2023 | Oct 30, 2022 | $69.67B | Dec 15, 2023 |
| FY2022 | Oct 31, 2021 | $65.68B | Dec 15, 2022 |
| FY2021 | Nov 1, 2020 | $62.15B | Dec 16, 2021 |
| FY2020 | Nov 3, 2019 | $61.58B | Dec 17, 2020 |
| FY2019 | Oct 28, 2018 | $58.80B | Dec 19, 2019 |
| FY2018 | Oct 29, 2017 | $56.21B | Dec 17, 2018 |
| FY2016 | Oct 31, 2016 | $51.44B | Dec 19, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $25.95B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $22.84B | Dec 18, 2025 |
| FY2024 | Oct 29, 2023 | $21.79B | Dec 12, 2024 |
| FY2023 | Oct 30, 2022 | $20.26B | Dec 15, 2023 |
| FY2022 | Oct 31, 2021 | $18.43B | Dec 15, 2022 |
| FY2021 | Nov 1, 2020 | $12.94B | Dec 16, 2021 |
| FY2020 | Nov 3, 2019 | $11.41B | Dec 17, 2020 |
| FY2019 | Oct 28, 2018 | $11.29B | Dec 19, 2019 |
| FY2018 | Oct 29, 2017 | $9.56B | Dec 17, 2018 |
| FY2016 | Oct 31, 2016 | $6.52B | Dec 19, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $4.19B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $3.96B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $3.90B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $3.69B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $3.29B | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $3.08B | Dec 15, 2022 |
| FY2021 | Nov 3, 2019 | $2.92B | Dec 16, 2021 |
| FY2020 | Oct 28, 2018 | $3.10B | Dec 17, 2020 |
| FY2019 | Oct 29, 2017 | $1.03B | Dec 19, 2019 |
| FY2016 | Oct 31, 2016 | $815.70M | Dec 19, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $59.68B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $56.40B | Dec 18, 2025 |
| FY2024 | Oct 29, 2023 | $50.93B | Dec 12, 2024 |
| FY2023 | Oct 30, 2022 | $42.25B | Dec 15, 2023 |
| FY2022 | Oct 31, 2021 | $36.45B | Dec 15, 2022 |
| FY2021 | Nov 2, 2020 | $31.61B | Dec 16, 2021 |
| FY2021 | Nov 1, 2020 | $31.65B | Dec 16, 2021 |
| FY2020 | Nov 3, 2019 | $29.85B | Dec 17, 2020 |
| FY2019 | Oct 28, 2018 | $27.55B | Dec 19, 2019 |
| FY2018 | Oct 29, 2017 | $25.30B | Dec 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $8.28B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $7.32B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $7.46B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $4.77B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $8.02B | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $7.07B | Dec 15, 2022 |
| FY2020 | Nov 3, 2019 | $3.86B | Dec 17, 2020 |
| FY2019 | Oct 28, 2018 | $3.90B | Dec 19, 2019 |
| FY2018 | Oct 29, 2017 | $9.33B | Dec 17, 2018 |
| FY2016 | Oct 31, 2016 | $4.34B | Dec 19, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | 18 | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | 25 | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | 34 | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | 23 | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | 19 | Dec 15, 2023 |
| FY2020 | Nov 1, 2020 | 2 | Dec 17, 2020 |
| FY2020 | Aug 2, 2020 | 2 | Dec 17, 2020 |
| FY2020 | May 3, 2020 | 2 | Dec 17, 2020 |
| FY2020 | Feb 2, 2020 | 1 | Dec 17, 2020 |
| FY2020 | Nov 3, 2019 | 2 | Dec 17, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | 18 | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | 25 | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | 34 | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | 23 | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | 18 | Dec 15, 2023 |
| FY2020 | Nov 1, 2020 | 2 | Dec 17, 2020 |
| FY2020 | Aug 2, 2020 | 2 | Dec 17, 2020 |
| FY2020 | May 3, 2020 | 2 | Dec 17, 2020 |
| FY2020 | Feb 2, 2020 | 1 | Dec 17, 2020 |
| FY2020 | Nov 3, 2019 | 2 | Dec 17, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | 270.40M | Dec 18, 2025 |
| FY2024 | Oct 27, 2024 | 271.80M | Dec 12, 2024 |
| FY2023 | Oct 29, 2023 | 281.60M | Dec 15, 2023 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 2, 2025 | $1.72B | Dec 18, 2025 |
| FY2025 | Oct 27, 2024 | $1.61B | Dec 18, 2025 |
| FY2025 | Oct 29, 2023 | $1.43B | Dec 18, 2025 |
| FY2024 | Oct 30, 2022 | $1.31B | Dec 12, 2024 |
| FY2023 | Oct 31, 2021 | $1.04B | Dec 15, 2023 |
| FY2022 | Nov 1, 2020 | $956.00M | Dec 15, 2022 |
| FY2021 | Nov 3, 2019 | $943.00M | Dec 16, 2021 |
| FY2020 | Oct 28, 2018 | $806.00M | Dec 17, 2020 |
| FY2019 | Oct 29, 2017 | $764.00M | Dec 19, 2019 |
| FY2016 | Oct 31, 2016 | $761.30M | Dec 19, 2016 |